OptiRTP Briefs U.S. Consulate and Commercial Service on U.S. Market Strategy
Left to right: Jonathan Watt, Commercial Specialist, U.S. Commercial Service; Bogdan Anich, Founder and Director, OptiRTP; Steve Knode, Senior Commercial Officer–Oceania, U.S. Commercial Service; Jon Doherty, CEO, OptiRTP. Photo: OptiRTP.
OptiRTP CEO Jon Doherty and Founder and Director Bogdan Anich met with the United States Consulate General and the U.S. Commercial Service in Auckland on 4 March 2026 to discuss the company’s United States market strategy.
The meeting included U.S. Consul General Melissa Sweeney, Senior Commercial Officer–Oceania Steve Knode, visiting from the U.S. Commercial Service office in Sydney, and Jonathan Watt, Commercial Specialist with the U.S. Commercial Service in Auckland.
During the discussion, OptiRTP outlined its planned sequence for entering and expanding in the United States, including the operational steps the company is taking to establish its presence, build partnerships across key sectors, and progress its intended FDA De Novo regulatory pathway.
The meeting coincided with Knode’s visit to New Zealand and formed part of OptiRTP’s ongoing engagement with the U.S. Commercial Service, which assists companies in navigating the process of setting up and growing operations in the U.S. market. OptiRTP continues to advance its United States market strategy across regulatory, operational, and partnership workstreams.
About OptiRTP
OptiRTP (Return to Play) is a New Zealand-based biotech company. Its core technology, OBST (Optimum Bio Sound Therapy), has 352,000+ documented therapy hours with zero serious adverse events reported. OBST is an FDA-registered Class I medical device, 510(k)-exempt (registration and listing, not FDA clearance or approval), that uses dynamic, patterned acoustic neuromodulation via the auditory pathway, with a proposed mechanism involving modulation of central autonomic regulatory networks associated with sleep, pain, recovery and stress regulation. Drug-free and non-invasive, used passively during sleep or rest through a tablet and earbuds. Users can follow recovery markers on their own wearable.
